Key Event Details
An Administrative Committee of the Board of Directors of AstraZeneca Pharma India Limited approved the surrender of the company's factory license to the Department of Factories, Boilers, Industrial Safety and Health for cancellation. This approval was granted on June 3, 2026.
Historical Context
This intimation follows two previous communications to the stock exchanges:
- June 21, 2024: Intimation regarding exit from the manufacturing site
- September 2, 2025: Intimation regarding surrender of the manufacturing license
License Details
The surrendered factory license had the following characteristics:
- Validity Period: From December 14, 2023 to December 31, 2026
- Regulatory Authority: Department of Factories, Boilers, Industrial Safety and Health
- Action Taken: Surrender for cancellation
Impact Assessment
According to the annexure submitted:
- Impact/relevance of such approval/license to the listed entity: Not applicable
- Withdrawal/cancellation or suspension impact: Not applicable
- Actual monetary impact: Not applicable
- Corrective actions taken: Not applicable
Financial Impact
The disclosure explicitly states that financial impact is "Not applicable" in multiple sections of the regulatory annexure. No monetary impact or corrective actions are quantified in the filing.